RxDoctor Payments Data

Matthew McLeod, MD

Plastic Surgery · Savannah, GANPI 1699933093

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 40.8% of the total. Reporting peaked in 2023 at $3,317 and has fallen 84.3% since, to $519 in 2025.

$9,456in general payments, 2019–2025

Across 171 payments — averaging $55.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • TELA Bio, Inc.$2K
  • Zimmer Biomet$618
  • Mentor Worldwide LLC$594
  • Galderma Laboratories, L.p.$428
  • Merz North America, Inc.$372
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$4,53248%
  • Food & beverage$4,89152%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,456 in reported general payments places this provider in the 80th percentile of 163 plastic surgery providers in Georgia.

See all plastic surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$38,648
Medicare patients
44
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Imiquimod13$195
Celecoxib14$111
Gabapentin15$44

Paid to pharmacies, not to this prescriber.

Other plastic surgery in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →